Profil Financier
Zhu Yi occupe actuellement le rang #329 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $10.8 B (+$286 sur 24h).
Zhu Yi is the chairman of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments.
The company went public in Shanghai in 2023, raising $136 million; it has been seeking a Hong Kong IPO since 2024.
Biokin's U.S. subsidiary SystImmune signed in 2023 an $8.4 billion deal with Bristol Myers Squibb to jointly develop and commercialize a potential cancer treatment worldwide.
Zhu taught immunology and microbiology at West China University of Medical Sciences before striking out on his own.
Zhu has a master's in biology from Fudan University and a doctorate in management from Sichuan University.